BiotechTube
Acerta Pharma

Acerta Pharma

Oss, Netherlands· Est.
acerta-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $350M

Overview

Acerta Pharma, founded in 2012 and fully acquired by AstraZeneca in 2021, is a biotechnology company focused exclusively on haematology. It operates as AstraZeneca's dedicated European R&D hub for blood cancers, utilizing a proprietary covalent binding technology platform to discover and develop targeted small molecule therapies. The company's strategy is centered on addressing high unmet needs in over 130 types of blood cancers through innovative clinical strategies, including combination therapies. Its pipeline and research efforts are deeply integrated with AstraZeneca's broader oncology portfolio and resources.

HaematologyOncology

Technology Platform

Covalent binding technology for designing irreversible, highly selective small molecule inhibitors, supported by multi-omic profiling and resistance biology research.

Funding History

1
Total raised:$350M
Series A$350M

Opportunities

The large and growing global market for haematological cancers, with over 130 disease types and significant unmet needs, presents a major opportunity.
Leveraging covalent technology to develop best-in-class or first-in-class agents, and combining them within AstraZeneca's broad oncology portfolio, can create differentiated, highly effective treatment regimens.

Risk Factors

Intense competition in the haematology space, particularly from other BTK inhibitors and novel modalities like CAR-T therapies, poses a significant market risk.
Furthermore, as part of a large pharma, there is inherent strategic risk that internal priorities may shift, and the always-present risk of clinical trial failures for new pipeline candidates remains.

Competitive Landscape

Acerta operates in the highly competitive haematology therapeutics market. Its key asset, acalabrutinib, competes directly with other BTK inhibitors like ibrutinib (AbbVie/J&J) and zanubrutinib (BeiGene). The broader competitive set includes large pharma and biotech companies developing CD19-directed CAR-T therapies, bispecific antibodies, and other novel mechanism drugs for blood cancers.

More companies in Small Molecule Drugs →More companies in Netherlands →